Vendor, Exton, PA
Lungpacer Medical USA Inc.
UEI EM2BL19AALM8, CAGE 8K9A8
1 award and $0 obligated between August 12, 2026 and August 12, 2026, 100% under full and open competition, against 100.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00021Definitive Contract, August 12, 2026, Full and Open Competition, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Lungpacer Medical USA INC Lung-Protective Effects of Transvenous Diaphragm Activation in Patients with Ards Aoi #12: Mitigating Long-Term EfNAICS 541714, PSC AN13 | $0 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 1 across 1 awards